Pharsight

Gimoti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11628150 EVOKE PHARMA INC Nasal formulations of metoclopramide
Dec, 2029

(6 years from now)

US11020361 EVOKE PHARMA INC Nasal formulations of metoclopramide
Dec, 2029

(6 years from now)

US8334281 EVOKE PHARMA INC Nasal formulations of metoclopramide
May, 2030

(6 years from now)

Gimoti is owned by Evoke Pharma Inc.

Gimoti contains Metoclopramide Hydrochloride.

Gimoti has a total of 3 drug patents out of which 0 drug patents have expired.

Gimoti was authorised for market use on 19 June, 2020.

Gimoti is available in spray, metered;nasal dosage forms.

Gimoti can be used as nasal administration of metoclopramide for treatment of diabetic gastroparesis.

The generics of Gimoti are possible to be released after 16 May, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 19, 2023

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of GIMOTI before it's drug patent expiration?
More Information on Dosage

GIMOTI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic